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Neuropathic pain, a debilitating pain condition, is a common consequence of damage to
the nervous system. Neuropathic pain is often resistant to currently available analgesics.
A growing body of evidence indicates that spinal microglia react and undergo a series
of changes that directly influence the establishment of neuropathic pain states. After
nerve injury, P2X4 receptors (P2X4Rs) are upregulated in spinal microglia by several
factors at the transcriptional and translational levels. Those include the CC chemokine
CCL21 derived from damaged neurons, the extracellular matrix protein fibronectin in the
spinal cord, and the transcription factor interferon regulatory factor 8 (IRF8) expressed
in microglia. P2X4R expression in microglia is also regulated at the post-translational
level by signaling from other cell-surface receptors such as CC chemokine receptor
(CCR2). Importantly, inhibiting the function or expression of P2X4Rs and P2X4R-regulating
molecules suppresses the aberrant excitability of dorsal horn neurons and neuropathic
pain. These findings indicate that P2X4R-positive microglia are a central player in
mechanisms for neuropathic pain. Thus, microglial P2X4Rs are a potential target for
treating the chronic pain state.
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INTRODUCTION
Injury to the nervous system arising from bone compression
in cancer, diabetes mellitus, infection, autoimmune diseases, or
traumatic injury results in debilitating chronic pain states (so-
called neuropathic pain). Characteristic symptoms of neuropathic
pain include spontaneous pain, hyperalgesia (increased pain per-
ception of noxious stimuli), and tactile allodynia (pain hyper-
sensitivity to normally innocuous stimuli). Neuropathic pain is
refractory to currently available treatments, such as non-steroidal
anti-inflammatory drugs and opioids (Costigan et al., 2009).
Neuropathic pain is now considered not just a symptom of disease
but also the consequence of disordered functioning of the nervous
system (Costigan et al., 2009; Beggs et al., 2012).
Extensive lines of evidence from basic pain research using
diverse animal models of neuropathic pain indicated that neu-
ropathic pain is a reflection of the aberrant excitability of dorsal
horn neurons evoked by peripheral sensory inputs (Woolf and
Salter, 2000; Costigan et al., 2009). While neurons have long been
considered the only cell type involved in neuropathic pain, recent
studies have shown that pathologically altered neurotransmission
requires communication with glial cells, in particular microglia,
activated in the spinal cord in response to peripheral nerve injury
(PNI; Watkins et al., 2001; Tsuda et al., 2005; McMahon and
Malcangio, 2009; Ren and Dubner, 2010; Tsuda et al., 2013).
Microglial cells are resident macrophages in the central
nervous system (CNS), which derive from primitive macrophages
in the yolk sac (Ginhoux et al., 2010). In the adult, microglia
are ubiquitously distributed throughout the brain and spinal
cord and have small cell body bearing branched and motile
processes, which monitor the local environment in the CNS
(Davalos et al., 2005; Nimmerjahn et al., 2005). Microglia
show a stereotypical long-term response to a wide range of
stimuli that threaten physiological homeostasis, including PNI.
In response to PNI, microglia activation in the spinal cord
progresses through hypertrophic morphology, an increase in
cell number, and altered gene expression (Tsuda et al., 2005;
Suter et al., 2007; Tsuda et al., 2009b). Activated microglia
induce or enhance expression of various genes including
neurotransmitter receptors such as purinergic P2 receptors
(Pocock and Kettenmann, 2007). By responding to extracellular
stimuli such as ATP, activated glia evoke various cellular responses
such as production and release of bioactive factors including
cytokines and neurotrophic factors (Inoue, 2006), which in turn
leads to hyperexcitability of dorsal horn neurons and neuropathic
pain.
Among purinergic P2 receptors [ionotropic receptors (P2XRs)
andmetabotropic receptors (P2YRs)], activated microglia express
several subtypes of P2XRs and P2YRs, and these receptors play a
key role in establishing and maintaining neuropathic pain states
(Tsuda et al., 2012, 2013). In this article, we highlight recent
advances that further increase our understanding of the mecha-
nisms underlying neuropathic pain, with a specific focus on P2X4
receptor (P2X4R) in spinal microglia after PNI.
P2X4R IN SPINAL MICROGLIA AND NEUROPATHIC PAIN
The first observation that demonstrated the important role of
P2X4R in neuropathic pain was that established tactile allodynia
after PNI was reversed by pharmacological blockade of P2X4Rs
in the spinal cord (Tsuda et al., 2003). Immunohistochemical
studies revealed that expression of P2X4Rs in the spinal cord was
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 191 | 1
Tsuda et al. P2X4 receptors and neuropathic pain
upregulated exclusively in microglia. These results indicated that
PNI-induced pain hypersensitivity depended on ongoing signal-
ing via microglial P2X4Rs. Furthermore, animals with P2X4R
knock-down or knock-out in the spinal cord were resistant to
PNI-induced tactile allodynia (Tsuda et al., 2003; Ulmann et al.,
2008; Tsuda et al., 2009a), indicating a necessity for P2X4Rs. The
impact of microglial P2X4R stimulation in transforming tactile
information to pain was demonstrated by an in vivo microglia
transfer approach (Tsuda et al., 2003). It was found that intrathe-
cal delivery of P2X4R-stimulated microglia caused normal rats to
develop allodynia and indicated that microglial P2X4R stimula-
tion is sufficient (Tsuda et al., 2003, 2005). Furthermore, it was
demonstrated that activation of microglial P2X4Rs stimulated
the synthesis and release of brain-derived neurotrophic factor
(BDNF; Ulmann et al., 2008; Trang et al., 2009) and that BDNF
then causes an altered transmembrane anion gradient in a sub-
population of dorsal horn lamina I neurons presumably through
the downregulation of the neuronal chloride transporter KCC2,
which in turn renders GABA and glycine effects depolarizing,
rather than hyperpolarizing, in these neurons (Coull et al., 2005;
Figure 1). Thus, P2X4R-stimulated microglia release BDNF as
a crucial factor to signal lamina I neurons, causing an aberrant
nociceptive output that contributes to neuropathic pain (Beggs
et al., 2012). Therefore, microglial P2X4Rs are central players in
the pathogenesis of neuropathic pain.
REGULATION OF P2X4R EXPRESSION IN MICROGLIA:
TRANSCRIPTIONAL, TRANSLATIONAL, AND POST-TRANSLATIONAL
LEVELS
Upregulation of P2X4R expression in microglia is a key process in
the pathogenesis of neuropathic pain. Several studies have identi-
fied molecules involved in the upregulation of P2X4R expression
in spinal microglia after PNI.
A clue to identifying an inducer of P2X4R expression in
microglia was that microglial P2X4R upregulation was observed
following PNI but not peripheral tissue inflammation (Tsuda
et al., 2003), raising the possibility that a factor derived from
injured primary afferent sensory neurons might be involved.
Recently, it was shown that the chemokine CCL21 [chemokine
(C-C motif) ligand 21] was induced in injured dorsal root
ganglion (DRG) neurons and transported to the central terminals
of the dorsal horn (Biber et al., 2011). Mice treated with
CCL21-neutralizing antibody and mice deficient for CCL21
showed attenuation of tactile allodynia and microglial P2X4R
upregulation. CCL21 treatment increased the expression of
P2X4R in cultured microglia, indicating a direct action of CCL21
on microglia. Intrathecal supply of CCL21 in CCL21-deficient
mice rescued PNI-induced tactile allodynia in those mice. Thus,
CCL21 derived from injured DRG neurons directly contributes to
microglial P2X4R expression and neuropathic pain (Biber et al.,
2011; Figure 1).
Because blood–spinal cord barrier functions collapse after PNI
occurs (Beggs et al., 2010; Echeverry et al., 2011), proteins leaking
from the blood might change P2X4R expression in microglia.
The extracellular matrix protein fibronectin might be such a
protein. The level of fibronectin protein was elevated in the dorsal
horn after PNI (Nasu-Tada et al., 2006; Echeverry et al., 2011).
Fibronectin stimulation induces upregulation of P2X4R mRNA
and protein in primary cultured microglial cells (Nasu-Tada et al.,
2006). Using integrin blockers in vitro and in vivo, it was shown
that fibronectin/integrin signaling was crucial for augmentation
of P2X4R expression and PNI-induced tactile allodynia (Tsuda
et al., 2008a). Furthermore, intrathecal injection of fibronectin to
naïve animals produced tactile allodynia, a behavior not observed
in P2X4R-deficient mice administered fibronectin (Tsuda et al.,
2008a). Regarding intracellular signaling mechanisms underly-
ing P2X4R upregulation by fibronectin, microglial Lyn tyrosine
kinase, a member of Src-family kinases (SFKs) that belong to
the non-receptor protein tyrosine kinase family, is an important
molecule as upregulation of P2X4R gene expression in response to
fibronectin is not observed in microglial cells lacking Lyn (Tsuda
et al., 2008b). In spinal cord microglial cells, Lyn was the predom-
inant SFK (Tsuda et al., 2008b) amongst the five members (Src,
Fyn, Lck, Yes, and Lyn) that are known to be expressed in the CNS
(Salter and Kalia, 2004). Lyn expression in the spinal cord in vivo
is highly restricted to microglia, and following PNI the level of Lyn
is increased (Tsuda et al., 2008b), which is interferon-γ signaling
dependent (Tsuda et al., 2009b). Mice lacking Lyn suppress PNI-
induced tactile allodynia and the upregulation of spinal P2X4R
expression after PNI (Tsuda et al., 2008b). Following Lyn tyrosine
kinase activation, two intracellular signaling cascades are dis-
tinctly activated: one is a pathway through phosphatidylinositol
3-kinase (PI3K)-Akt and the other is through mitogen-activated
protein kinase kinase (MAPK kinase, MEK)-extracellular signal-
regulated kinase (ERK; Tsuda et al., 2009c). Signaling through the
PI3K-Akt pathway induced degradation of p53 via mouse double
minute 2 in a proteasome-dependent manner. The consequence
of an attenuated repressive effect of p53 may be associated with
enhanced P2X4 gene expression. However, activated MEK-ERK
signaling in microglia exposed to fibronectin enhanced eukary-
otic translation initiation factor 4E (eIF4E) phosphorylation sta-
tus via activated MAPK-interacting protein kinase-1, which may
play a role in regulating P2X4 expression at translational levels
(Figure 1). The Lyn-ERK signaling pathway seems likely to be
active in spinal microglia after PNI as pharmacological inhibition
of SFK effectively suppressed ERK activity in spinal microglia
(Katsura et al., 2006). Thus, Lyn might be a key kinase in the
molecular machinery mediating the upregulation of P2X4R in
microglia (Figure 1).
To detect extracellular ATP, P2X4Rs are expressed on the
cell surface of microglia. However, a large amount of P2X4R
protein within microglia (and macrophages) localizes predomi-
nantly to intracellular lysosomal compartments (Qureshi et al.,
2007). Interestingly, P2X4R protein remains stable within the
proteolytic environment of lysosomes. How P2X4R protein is
recruited to the cell surface of microglia remains elusive, but
recent studies have shown that trafficking of P2X4R protein to
the cell surface occurs when microglia are stimulated by a Toll-
like receptor (TLR)4 agonist lipopolysaccharide (Boumechache
et al., 2009; Toulme et al., 2010) or the Ca2+ ionophore, iono-
mycin (Qureshi et al., 2007). Furthermore, the chemokine CCL2
increased P2X4R protein levels on the cell surface (without chang-
ing total cellular expression) via CC chemokine receptor (CCR2)
(Toyomitsu et al., 2012). Notably, CCL2 changed the distribution
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FIGURE 1 | Schematic illustration of the potential mechanisms by which
P2X4R in activated microglia modulate pain signaling in the dorsal horn
after PNI. Nerve injury activates microglia in the dorsal horn of the spinal
cord. Activated microglia show increased expression of P2X4R. The
upregulation of microglial P2X4R expression involves signaling by fibronectin
and chemokine (C-C motif) ligand 21 (CCL21). CCL2 signaling promotes
P2X4R trafficking to cell surface of microglia. P2X4R is activated by ATP and,
in turn, release bioactive diffusible factors, such as BDNF. BDNF
downregulates the potassium-chloride transporter KCC2 via TrkB, causes an
increase in intracellular [Cl−], and leads to the collapse of the transmembrane
anion gradient in dorsal horn neurons which in turn induces depolarization of
these neurons following stimulation by GABA and glycine. The resultant
hyperexcitability in the dorsal horn pain network induced by factors from
activated microglia may be responsible for neuropathic pain.
of lysosomes with P2X4R protein within microglial cells and
induced the release of a lysosomal enzyme (Toyomitsu et al.,
2012). Thus, CCL2 might promote the expression of P2X4R
protein on the cell surface of microglia through exocytosis of
P2X4R-containing lysosomes (Figure 1). A recent study using
single-molecule imaging to track P2X4Rs in the processes of
microglia showed that lateral mobility of P2X4Rs is enhanced
in activated microglia by the p38 MAPK pathway that selec-
tively regulates slowly mobile P2X4Rs (Toulme and Khakh, 2012).
These results indicated that microglial P2X4Rs are dynamically
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regulated on the cell surface (Figure 1). Thus, post-translational
regulation to enhance P2X4R expression and mobility on the
cell surfaces of microglia might render cells hyper-responsive
to extracellular ATP, which may be important in neuropathic
pain.
TRANSCRIPTIONAL FACTOR FOR REACTIVE STATES OF MICROGLIA
PNI activates microglia and converts them to reactive phenotypes
through the activation of gene transcription. For example,
as described above, activated microglia with high levels of
P2X4R expression are essential for PNI-induced neuropathic
pain. Appropriate changes in gene expression patterns required
for transformation into reactive phenotypes might be tightly
regulated by cell type-specific transcription factors. Recent
studies identified interferon regulatory factor 8 (IRF8) as a
transcription factor in microglia (Horiuchi et al., 2012; Masuda
et al., 2012; Minten et al., 2012; Kierdorf et al., 2013) that
was critical for their activation and neuropathic pain (Masuda
et al., 2012). IRF8 is a member of the IRF family (IRF1–9),
and is expressed in immune cells such as lymphocytes and
dendritic cells (Tamura et al., 2008). Within the spinal cord,
IRF8 expression was markedly upregulated in microglia, but
not in neurons or astrocytes, after PNI (Masuda et al., 2012).
The microglia-specific upregulation of IRF8 occurs as early as
postoperative day 1, peaks on day 3, and persists for at least
several weeks. IRF8-deficient mice showed a reduction of PNI-
induced tactile allodynia with no change in basal mechanical
sensitivity. Notably, suppressing the upregulated expression of
spinal IRF8 after PNI by intrathecal administration of a small
interfering RNA (siRNA) targeting IRF8 in wild-type mice with
allodynia caused a significant recovery of tactile allodynia. This
indicated an ongoing activation of IRF8 in spinal microglia.
In vitro and in vivo studies demonstrated that IRF8 promoted
the transcription of P2X4R and other molecules associated
with reactive phenotypes [innate immune response (TLR2),
chemotaxis (P2Y12R and the chemokine receptor CX3CR1),
and inflammatory components (interleukin-1β, cathepsin S,
and BDNF)]. Nevertheless, nerve injury-induced proliferation of
spinal microglia was not affected by IRF8 deficiency, indicating
IRF8 deficiency does not impair all reactive processes ofmicroglia.
Rather the transcription factor contributes to determining the
reactive phenotypes of microglia by changing the expression
of a set of genes including P2X4R (Figure 1). However, several
important issues remain. How is IRF8 expression induced
in microglia after PNI? To determine whether IRF8 directly
binds to promoter regions of these genes is also important.
Answers to these issues will provide new insights into the
molecular mechanisms underlying microglial activation and
neuropathic pain.
MARKERS OF ACTIVATED MICROGLIA IN VIVO
A widely used index for predicting the status of microglia activity
in vivo is the expression levels of microglial markers [complement
receptor 3 (CR3, recognized by OX-42) and Iba1]. Increased
immunolabeling of these markers is a principal feature of a
variety of PNI models (Tsuda et al., 2005; Suter et al., 2007),
but it remains unclear whether their expression can be linked to
tactile allodynia following PNI as in some cases CR3 expression is
not well correlated with the degree of allodynia (Colburn et al.,
1997; Winkelstein and DeLeo, 2002; Tsuda et al., 2005; Suter
et al., 2007). In addition, OX-42 immunofluorescence was still
observed in P2X4R-knockdown animals that had attenuated PNI-
induced allodynia (Tsuda et al., 2003). In contrast, as described
above, microglia-specific molecules including P2X4R and IRF8
are necessary for the pathology of neuropathic pain, in both its
development and maintenance phases. Therefore, alterations in
the expression or phosphorylation of these molecules are likely
to be more useful markers to assess reactive states of microglia in
vivo.
CONCLUDING REMARKS
We have primarily focused on the role of P2X4R expressed in
spinal microglia in neuropathic pain (Figure 1). Pharmacological,
molecular, and genetic studies on P2X4Rs described above
provide compelling evidence that P2X4R-positive microglia are a
central player in the mechanisms of neuropathic pain and might
be promising targets for treating neuropathic pain. Furthermore,
the upregulation of microglial P2X4R expression has also been
reported in animal models of stroke (Cavaliere et al., 2003),
brain tumor (Guo et al., 2004), traumatic brain injury (Guo and
Schluesener, 2005; Zhang et al., 2007), spinal cord injury (Schwab
et al., 2005), epilepsy (Ulmann et al., 2013), and in human acute
inflammatory demyelinating polyradiculoneuropathy (Zhang
et al., 2008). Recently, it was demonstrated that P2X4R-positive
microglia are essential for morphine-induced hyperalgesia via
a P2X4R-BDNF-KCC2 disinhibition cascade between microglia
and dorsal horn neurons (Ferrini et al., 2013). It is expected
that an increased understanding of the phenotype of P2X4R-
positive microglia will provide us with exciting insights into pain
mechanisms and clues to aid the development of new therapeutic
agents for the management of neuropathic pain and other CNS
diseases.
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